Tango Therapeutics, Inc.
TNGXTango Therapeutics, Inc. (TNGX) is a biotechnology company focused on developing targeted cancer therapies. The company leverages genetic and genomic research to identify vulnerabilities in cancer cells, aiming to create precision medicines that selectively attack tumors while minimizing effects on normal tissue. Founded with a focus on innovative and personalized cancer treatments, Tango Therapeutics is engaged in the discovery and development of novel therapeutic candidates.
Company News
Tango Therapeutics priced an underwritten offering of 18.2 million shares at $30.00 per share and pre-funded warrants, expected to raise approximately $600 million in gross proceeds. The offering is expected to close on June 11, 2026, with J.P. Morgan, Leerink Partners, Cantor, and Stifel serving as joint bookrunning managers.
RTW Investments purchased 16,010,524 shares of Erasca for approximately $189.23 million in Q1 2026, with the position's value rising to $261.42 million by quarter-end. The clinical-stage biotech company, which develops oral inhibitors targeting the RAS/MAPK pathway for cancer treatment, has seen its stock surge 800% over the past year. The invest...
RTW Investments, a biotech-focused fund, purchased 11.8 million shares of Tango Therapeutics for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of AUM. The purchase comes as TNGX stock has surged 840% over the past year. The investment reflects confidence in Tango's lead candidate vopimetostat and upcoming clinical d...
Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising ca...
Tango Therapeutics announced that its Compensation Committee granted a new employee 367,500 non-qualified stock options at an exercise price of $11.94 per share and 60,000 restricted stock units (RSUs) under the company's 2023 Inducement Plan. The options vest 25% after one year with monthly vesting thereafter, while RSUs vest in three tranches o...
